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Poster Session-I 952006, autologous (N 5 661), allogeneic (N 5 254), syngeneic (N
5 3), and umbilical cord blood (N 5 77) HSCT. Peripheral blood
(N 5 849) and bone marrow (N 5 69) stem cells were used as
graft sources. Overall, 624 infections were identified (608 cul-
ture-positive) in 385 HSCT pts median age 46 years (male 5
187, female 5 198). HSCT were performed primarily for AML
(N 5 105) and NHL (N 5 79). Documented infections were in-
cluded if they occurred during an inpatient admission within 1
month (mo) prior to and 1–12 mo after HSCT. Several pts had
received multiple HSCT or donor lymphocyte infusions; each
was counted only if there was a documented infection during the
designated time frame. Median (range) number infections/mo
was 4 (1–12). During 9 separate mos in this 13 yr period, there
were $10 infections/mo. A total of 333 bloodstream infections
were identified.
Bloodstream GI Infections
Infections (N5333) N (%) (N5113) N (%)Candida/other
yeast9 (3%) Candida/other
yeast27 (24%)Coagulase negative
Staphylococcus100 (30%) Clostridium difficile
toxin positive75 (66%)Escherichia coli 27 (8%) Rotavirus antigen
positive6 (5%)Enterobacter cloacae 12 (4%)
Enterococcus faecalis 7 (2%) Genitourinary
Infections (N598)
N (%)Enterococcus faecium
excluding VRE5 (2%) Enterococcus
including VRE24 (24%)Klebsiella oxytoca 6 (2%) Escherichia coli 22 (22%)
Klebsiella pneumoniae 36 (11%) Klebsiella pneumoniae 9 (9%)
MRSA 3 (1%)
Pseudomonas aeruginosa 13 (4%) Pulmonary
Infections (N535)
N (%)Viridans group
Streptococcus13 (4%) Aspergillus
species4 (11%)Staphylococcus aureus
excluding MRSA13 (4%) Coagulase negative
Staphylococcus4 (11%)VRE 23 (7%) VRE 5 (14%)After bloodstream infections, nosocomial gastrointestinal (GI)
and genitourinary infections were most common. Infectious
pneumonia was uncommon with only 35 documented infections,
Aspergillus species was responsible for 11% (4/35). Gram positive
blood stream infections predominated, most likely associated
with central venous catheter use. Additionally, C. difficile infections
remained an important cause of morbidity and mortality. Despite
absence of global antibiotic prophylaxis (with the exception of
Pneumocystis pneumonia prophylaxis) and not routinely perform-
ing surveillance screening before/during HSCT, we note a low
infectious complication rate over the last 13 yrs. We attribute
our low overall infection rate and lack of major infectious out-
breaks to our system of monthly self-monitoring by our multi-
disciplinary team.CRA-DATA MANAGEMENT
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IMPLEMENTATION OF CHANGE TO THE NEW PATIENT REFERRAL
PROCESS
Willeford, J.F. Texas Oncology - Charles A. Sammons Cancer Center,
Dallas, TX
Prior to April 2008, the process of scheduling new patient office
visits with the Blood and Marrow Transplant physicians was housed
within the affiliated hospital. They were responsible for taking all
new referral phone calls, entering patient information into both phy-
sician and hospital management systems, and scheduling new patient
appointments. Unfortunately, it became evident that there was
a problem with communication and timely scheduling of patients
as the clinic began receiving complaints from referring physicians.It was also confusing for patients when receiving calls from the hos-
pital to schedule for the clinic. The clinic determined that it was nec-
essary to take over the referral process from the hospital.
Management wanted to ensure that referring physician and patient
needs were being met as well as regain control over a process that
directly affected the image of the clinic. It was redesigned to meet
the clinic’s needs:
0 The insurance verification reps absorbed taking the referral
calls. A log was created to track referrals and call backs with
a goal of returning initial calls within 24 hours.
0 A fax was installed at their desk to facilitate receiving medical
records timely.
0 All patient demographics/insurance information is collected
and entered into the clinic’s management system. The reps
began entering the information into the hospital’s management
system as well to simplify communication to the patient and
to the hospital. This minimized the number of calls to the
patient.
0 After verifying the patient’s insurance, the appointment is
scheduled. Since the process is housed in the clinic, communica-
tion has become easier with the physician coordinators thereby
increasing the ability to adjust the physician’s schedule in an
urgent situation.
0 The referring physician’s office is then informed of the
patient’s appointment assuring that the patient has been sched-
uled timely.
0 A packet is sent to the patient with an appointment re-
minder, maps, and necessary paperwork. Completing this
ahead of time saves the patient time once in the clinic. Since
making this change, the clinic has streamlined the new referral
process making great improvements. Referring physicians’
offices are well informed of their patient’s status in being
scheduled; therefore no complaints have been received since
April. In addition, communication amongst clinic and hospital
staff is much more efficient resulting in better customer service
to new patients.262
ALLOWING GREATER USE OF INSTITUTIONAL PRACTICE MAY DECREASE
COST OF CTN TRIALS
Ramakrishnan, A., Buck, T., Levine, J., James, P. University of Michi-
gan, Ann Arbor, MI
Data management for BMT studies can be a time consuming and
expensive task. Patients with complex diseases and complications
can make safety vigilance and protocol adherence a challenge.
When designing a trial, it is important to clearly delineate between
clinical practices that must be dictated because they are vital to the
integrity of the protocol versus ones that can be performed under
the Clinical Practice Guidelines (CPG) of an institution. Often,
when an institution is developing their own trial, they will routinely
allow CPG whenever possible. Trials that are designed by cooper-
ative groups or industry often have numerous specifications that
contradict CPG resulting in a greater data management burden
likely due to more time spent educating staff about differences,
more intensive screening, and reporting of additional data points.
To quantify the differences in data management (DM) hours we
compared DM time for four CTN trials to four similar University
of Michigan (UM) Investigator Initiated trials. This comparison
was facilitated by the routine use of a time and effort tracker tool
utilized by our center for every clinical research study. The time
tracker records the amount of time spent on various trial related
activities such as screening, data collection and safety reporting
for every trial. CTN trials average 31.4 hours more per patient
for data management than UM trials. Using the average cost for
a UM data manager of $29.10 per hour, the cost differential
exceeded $914 per patient. Aside from restricting the use of
CPG, other factors that may add to trial cost are 1) CTN staff
are remotely located and communication is therefore less efficient,
2) CTN trials require an average of 5.18 hours more to screen each
CTN Transplant Trials vs. Investigator Initiated Transplant Trials
U of M Investigator
Initiated Trials
DM hours
prior to
enrollment (1) Accrual
Date
1st patient
enrolled
Screening
Hours
Total Screen
hrs/ patient
DM Hr
After 1st
Enrollmment (2)
Total DM
Hrs/patient
Investigated Initiated Transplant
Conditioning (elderly AML)
28 12 05/18/2007 22 1.83 451 37.58
Investigator Initiated Transplant
Conditioning (CloBu4)
23 15 10/09/2007 30 2.00 305 20.33
Ph II Trial of Adjuvant Cellular
Immunotherapy for High-Risk
Hematologic Malignancy After
Reduced Intensity Allo SCT
Unk (3) 26 07/08/2003 97 3.73 1898 73.00
The addition of Etanercept to
Standard GVHD prophy in
Patients undergoing a full
intensity Unrelated donor
HSCT for the prevention
for Transplant Related
Complications
Unk (3) 71 12/06/2004 110 1.55 1770 24.93
Average
Screening
Hours/patient
2.28 Average DM
hours/patient
after 1st
enrollment
38.96
CTN Trials DM Hours
Prior to 1st
Enrollment (1)
Accrual Date 1st
Patient
Enrolled
Screening Hours Total Screen
Hrs/pt
DM Hr
after 1st
Enrollment (2)
Total DM
Hrs/patient
CTN 0501 71 4 02/03/2007 21 5.25 540 135
CTN 0401 28 11 12/06/2006 92 8.36 665 60.45
CTN 0402 150 10 01/04/2007 59 5.90 465 46.50
CTN 0201 31 12 11/22/2006 124 10.33 475 39.58
Average
Screening
Hours/patient
7.46 Average DM
hours/patient
after 1st
enrollment
70.38
(1) From ‘‘first effort logged’’ to
day prior to first enrollment
(2) Hours from 1st patient
enrolled through 5/30/2008
(3) First patient enrolled prior
to initiation of time tracker
96 Poster Session-Ipatient, likely due to more comprehensive testing to evaluate eligi-
bility, and 3) Differences in the amount of data collected may
account for some portion of the different expenditures in time
per patient. While potential savings are unlikely to be as high as
the total cost differential, at our center alone the total additional
expense for patients enrolled to the four CTN trials is almost
$33,000 for the effort reporting period examined. If CTN were
to write future protocols in a manner that allowed sites to follow
their institutional CPG whenever possible, there could be a signifi-
cant savings of time and money.263
SPECIALIZATION: FOCUSED EFFORT PRODUCES INCREASED ACCESS TO
BLOOD/MARROW TRANSPLANT PROGRAM
McClain, K.A. Baylor University Medical Center, Dallas, TX
Purpose: Due to the rising cost of healthcare and current eco-
nomic environment, many employers have made significant changes
to the healthcare coverage offered to their employees over the last
three to five years. Anticipating an increase in the number of patients
referred to our transplant program with benefit design limitations or
exclusions, as well as increased out-of-network referrals, a dedicated
Transplant Benefit Specialist (TBS) was hired to attempt to resolve
these issues on a case-by-case basis. Prior to implementing this staff-
ing change, only 11% of out-of-network blood/marrow transplant
patients were able to stay at Baylor University Medical Center via
a negotiated individual patient agreement between the payor, hospi-
tal and/or transplant physicians.
Method:TheTBS acts as the liaison between and among the hos-
pital, transplant physicians, payor, patient and employer ensuring
that all parties have all pertinent information in order to make aneducated decision on completing a one-time individual patient
agreement. The TBS advocates on behalf of the patient by providing
the following categories of information to the payor: clinical situa-
tion of the patient, BUMC’s outcomes for the particular transplant
type, rates/language available. In situations where a benefit design
maximum applies or a service is excluded from a policy, the TBS
assists the patient in submitting an exception request to the payor
or employer. The exception request typically includes a letter from
the consulting physician outlining the patient’s clinical situation
and suggested treatment protocol, a letter from the patient, as well
as a formal exception request letter from the TBS providing perti-
nent outcomes.
Results:The percent of converted out-of-network blood/marrow
cases increased from 11% in FY 05 to 62% in FY 07. The ability to
trend benefit design issues by payor has also resulted in changes to
the standard benefit offerings of major payors that previously were
outliers in our market.
Conclusion: A focused effort on this subset of patients dramati-
cally increased their access to our blood/marrow transplant program.
The data collected by the TBS has been a valuable tool used to edu-
cate payors and employers about their benefit design selection and its
impact on actual patient lives.264
DOCUMENTING DISEASE RESPONSE IN TRANSPLANT PATIENTS FOR THE
PURPOSE OF ACCURATE REPORTING TO THE CIBMTR
Thomas, T.K. St. Louis Children’s Hospital, Washington University,
St. Louis, MO
Background: Extracting accurate and relevant details regarding
disease response at fixed time-points as required by the Center for
